Adicet Bio, Inc.
ACET evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $59.4M
- Lead Asset:
- ADI-001 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ACET—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACET
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies, and solid tumors [news · published 2026-09-25].
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$59.4M
Cash Runway
—
Lead Asset
ADI-001 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials for Adicet Bio, Inc..
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies, and solid tumors [news · published 2026-09-25].
- Reported 12-month DORIS remission in 54% of evaluable SLE patients and complete renal response in 50% of evaluable lupus nephritis patients from the prula-cel Phase 1 study [news · published 2026-09-28].
- FDA cleared the IND for ADI-212, a CAR targeting PSMA with IL-12 armoring and CRISPR/Cas9 MED12 disruption, for metastatic castration-resistant prostate cancer; Phase 1 enrollment expected to begin in Q4 2026 [news · published 2026-08-27].
- Cash and equivalents of $33.1M as of 2026-06-30 [sec].
- Pipeline includes prula-cel (Phase 1 for lupus nephritis, SLE, and other autoimmune indications), ADI-212 (Phase 1 for mCRPC), and ADI-270 (Phase 1 for renal cell carcinoma) [pipeline].
- Prula-cel has received Fast Track designation from the FDA [pipeline].
What works
- Prula-cel Phase 1 data showed 54% 12-month DORIS remission in SLE and 50% complete renal response in lupus nephritis, supporting plans for pivotal study start-up in Q4 2026 [news · published 2026-09-28].
- The company has a differentiated allogeneic gamma delta CAR-T platform that may enable off-the-shelf use, potentially reducing manufacturing complexity and cost [news · published 2026-08-11].
- ADI-212 IND clearance for mCRPC expands the pipeline into a large oncology market with a novel mechanism (PSMA CAR, IL-12 armoring, MED12 disruption) [news · published 2026-08-27].
What to weigh
- The company reported a net loss of $21.4M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- ADI-212 faces a competitive landscape with 22 competitors including major pharma (Merck, AstraZeneca) in mCRPC [pipeline].
- Prula-cel is still in Phase 1; pivotal data and regulatory approval remain uncertain and years away [news · published 2026-09-28].
From the filings
Quoted directly from source documents.
Prula-cel Phase 1 efficacy results
“Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients”
News · September 28, 2026
ADI-212 IND clearance and planned Phase 1 start
“the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer”
News · August 27, 2026
Prula-cel Fast Track designation
“Regulatory Status: Fast Track”
Risks & what to watch (3)›
Key risks
- Cash burn rate — Net loss of $21.4M in the period ending 2026-06-30; cash of $33.1M may not sustain operations beyond 2027 without additional financing [sec].
- Competitive mCRPC landscape — ADI-212 enters a field with 22 competitors including Merck and AstraZeneca, many with later-stage assets [pipeline].
- Early-stage pipeline — All programs are Phase 1; no approved products; pivotal data for prula-cel not yet available [news · published 2026-09-28].
What to watch
- Initiation of prula-cel pivotal study start-up activities in Q4 2026 [news · published 2026-09-28].
- Phase 1 enrollment for ADI-212 in mCRPC expected to begin in Q4 2026 [news · published 2026-08-27].
- Future financing or partnership announcements given cash runway concerns [sec].
- Additional prula-cel data in other autoimmune indications (SSc, AAV, IIM, RA) listed in pipeline [pipeline].
Sources: News · Pipeline · Generated October 5, 2026 · How we verify sources →
Run Adicet Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adicet Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.23 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$42.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 1,182,624 | $8.1M |
| orbimed advisors llc | 1,027,944 | $7.0M |
| franklin resources inc | 626,571 | $4.3M |
| citadel advisors llc | 381,823 | $2.6M |
| vanguard capital management llc | 336,524 | $2.3M |
| woodline partners lp | 313,124 | $2.1M |
| adage capital partners gp, l.l.c. | 274,375 | $1.9M |
| prosight management, lp | 250,244 | $1.7M |
| renaissance technologies llc | 232,591 | $1.6M |
| stonepine capital management, llc | 221,955 | $1.5M |
Showing top 10 of 47 institutional holders of Adicet Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 8.1%
- Days to cover
- 5.9
- Shares short
- 656,546
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACET short interestGovernance
Frequently asked questions
What is the AI investment thesis for Adicet Bio, Inc.?
Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies, and solid tumors [news · published 2026-09-25].
What is Adicet Bio, Inc.'s lead drug candidate?
Adicet Bio, Inc.'s most advanced tracked candidate is ADI-001 (Phase 1) for Lupus Nephritis; Lymphoma, Follicular.
Who is the CEO of Adicet Bio, Inc.?
Mr. Chen Schor BA, CPA, M.B.A. is the chief executive officer of Adicet Bio, Inc. (ACET).
Where is Adicet Bio, Inc. headquartered?
Adicet Bio, Inc. (ACET) is headquartered in Boston, MA, United States.
What therapeutic areas does Adicet Bio, Inc. focus on?
Adicet Bio, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.